Nektar Therapeutics (NKTR) income statement
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)
Close on Nov 18, 2026Market cap $1.18BP/E –Yield –
Nektar Therapeutics income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 100.0%
- Operating margin
- -253.7%
- Net margin
- -297.1%
- Return on equity, FY2025
- -217.9%
Financial strength
- Current ratio
- 10.42
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 55.3%
Valuation
- P/E ratio
- –
- Price to sales
- 21.28
- Price to book
- 1.30
- Dividend yield
- –
See a number that looks wrong?